Intech Investment Management LLC Invests $368,000 in Janux Therapeutics, Inc. (NASDAQ:JANX)

Intech Investment Management LLC bought a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 8,108 shares of the company’s stock, valued at approximately $368,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD bought a new stake in shares of Janux Therapeutics in the 1st quarter worth approximately $739,000. Vanguard Group Inc. raised its stake in shares of Janux Therapeutics by 38.6% in the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after buying an additional 378,477 shares in the last quarter. Blue Owl Capital Holdings LP bought a new position in shares of Janux Therapeutics during the 2nd quarter worth about $1,676,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after acquiring an additional 339 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Janux Therapeutics by 234.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,048 shares of the company’s stock valued at $1,007,000 after acquiring an additional 16,864 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. Wedbush reaffirmed an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th. BTIG Research upped their price target on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a report on Thursday, November 7th. Finally, HC Wainwright upped their target price on shares of Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $77.90.

Insider Buying and Selling at Janux Therapeutics

In related news, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $42.33, for a total value of $92,364.06. Following the completion of the sale, the insider now owns 7,000 shares in the company, valued at $296,310. This represents a 23.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Andrew Hollman Meyer sold 50,000 shares of Janux Therapeutics stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $45.96, for a total value of $2,298,000.00. Following the transaction, the insider now owns 67,592 shares in the company, valued at approximately $3,106,528.32. This represents a 42.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 460,610 shares of company stock worth $21,583,666. Insiders own 29.40% of the company’s stock.

Janux Therapeutics Stock Up 49.0 %

Shares of JANX opened at $59.86 on Wednesday. The stock’s fifty day simple moving average is $49.60 and its 200-day simple moving average is $45.72. Janux Therapeutics, Inc. has a 12-month low of $7.79 and a 12-month high of $71.25.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The business’s revenue was down 82.6% on a year-over-year basis. As a group, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.